TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01475006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 595
Description: AMG 595 is an antibody drug conjugate that binds to EGFRvIII.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 595
Description: AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
Study: NCT03971266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Wear a Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Complete smartphone based PRO diary
Study: NCT04566705

Intervention type: OTHER
Intervention: Risks factors, maternal and neonatal outcomes/complications
Description: Risks factors, maternal and neonatal outcomes/complications
Study: NCT06332001

Intervention type: OTHER
Intervention: Experimental Group
Description: Listening of music of patient's choice during WB-MRI

Intervention type: OTHER
Intervention: Control Group
Description: Standard care condition during WB-MRI
Study: NCT03725865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Induction of neural stem cells
Description: Brain injection iNSC
Study: NCT00223353

Intervention type: OTHER
Intervention: Prosthetics, Orthotics and Physical Therapy
Description: Gait Analysis.

Intervention type: OTHER
Intervention: Prosthetics, Orthotics and Physical Therapy
Description: Gait Analysis.
Study: NCT00503711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100 mg every other day, 100mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100 mg every other day, 100mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Description: 300mg once daily
Study: NCT04172753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging on the MR Linac
Description: Only imaging performed on the MR Linac
Study: NCT01328236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome doxorubicin
Description: INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
Study: NCT01707368

Intervention type: DRUG
Intervention: Daivobet® Gel
Description: Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Study: NCT03923530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 50 mg daily
Study: NCT02728752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: Patients to be treated with Octagam 10%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients to be treated with a Placebo
Study: NCT04116853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPTIVE Extended-Care Program
Description: Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STATIC Extended-Care Program
Description: Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
Study: NCT01668693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERA (Endometrial Receptivity Array)
Description: The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERA (Endometrial Receptivity Array)
Description: The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Embryo Transfer
Description: When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Embryo Transfer
Description: When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second ERA
Description: A second ERA will be performed to confirm receptivity after further administration of Progesterone.
Study: NCT00511992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 IP day 2 every 21 days x 6 cycles
Study: NCT00975286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Description: Lantus® SoloStar® OptiClik®

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Description: Lantus® SoloStar® OptiClik®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study: NCT02034916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Study: NCT00975286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Description: TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiazolidinedione (TZD)
Description: TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
Study: NCT02099604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
Description: Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
Study: NCT04087356

Intervention type: GENETIC
Intervention: Blood draw
Description: Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.

Intervention type: GENETIC
Intervention: Blood draw
Description: Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
Study: NCT03753308

Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: 5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).

Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: 5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).

Intervention type: BIOLOGICAL
Intervention: Liver biopsy
Description: The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen

Intervention type: BIOLOGICAL
Intervention: Liver biopsy
Description: The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen
Study: NCT01105117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-385781A (Actelion Epoprostenol)
Description: per Prescribing Information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flolan®
Description: per Prescribing Information
Study: NCT01058785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lucanix
Description: Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
Study: NCT02111889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C] kinase inhibitor PET [15O]water PET and tumor biopsies.
Description: \[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
Study: NCT01824420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4mg QD and Oxybutynin ER 5mg QD
Description: Study group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4mg QD
Description: Control group
Study: NCT04748575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acai smoothie
Description: Smoothie containing 150g acai pulp

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo smoothie
Description: Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
Study: NCT00797017

Intervention type: DRUG
Intervention: fentanyl
Description: Infection, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: (CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: Bone Fracture, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: (FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: Other Deformity, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: (LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl
Description: Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
Study: NCT04282824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva
Study: NCT01486004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovysmen
Description: Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
Study: NCT02711501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted surgery.
Description: laser-assisted surgery
Study: NCT02627521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VerifyNow assay
Description: Platelet reactivity Units by VerifyNow assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerifyNow assay
Description: Platelet reactivity Units by VerifyNow assay
Study: NCT02711501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery by blade
Description: conventional surgery
Study: NCT02603757

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
Study: NCT02056717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administration of dexamethasone 10 mg IV 1 h before UAE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administration of normal saline 2 mL IV 1 h before UAE
Study: NCT01630759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
Study: NCT02794155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV Insulin Lispro
Description: HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Insulin Lispro: no bound insulin
Study: NCT01630759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
Study: NCT00003157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01498237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoacoustic endoprobe
Description: The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic endoscopy
Description: Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
Study: NCT02967094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of water before upper endoscopy
Study: NCT03826043

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample analysis
Description: Thrombophilia, blood count and coagulation count
Study: NCT00848263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plate
Description: Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal nail plate
Description: Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
Study: NCT00685529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic formoterol
Description: 12 µg of racemic formoterol fumarate BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: 15 µg of nebulized arformoterol tartrate inhalation solution BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic formoterol
Description: 24 µg of racemic formoterol fumarate BID
Study: NCT03914495

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
Study: NCT01220986

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: 0, 30, 60, 90 min post inflow-division
Study: NCT04404010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality
Description: Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical Technical Instructional Video
Description: Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
Study: NCT03528889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Extension and Derotation Osteotomy (ExtFDO)
Description: Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Extension and Derotation Osteotomy (ExtFDO)
Description: Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
Study: NCT04402853

Intervention type: DIAGNOSTIC_TEST
Intervention: Tears swab
Description: rtPCR on tears swabs samples
Study: NCT05341635

Intervention type: DIAGNOSTIC_TEST
Intervention: Swab sampling
Description: Collection of three nose-pharyngeal and oral swabs

Intervention type: DIAGNOSTIC_TEST
Intervention: Swab sampling
Description: Collection of three nose-pharyngeal and oral swabs
Study: NCT01492699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140
Description: 50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
Study: NCT01074658

Intervention type: DEVICE
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
Study: NCT04207320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: αβ+ T-cell depletion with Miltenyi CliniMACS system
Description: Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: αβ+ T-cell depletion with Miltenyi CliniMACS system
Description: Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.